Drug Trial Radar · NCT04550104
A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC
Last checked: Nov 20, 2026Latest source record: Dec 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Mar 17, 2021
Primary completion
Mar 2026
Study completion Mar 2028
Sponsor
- Lead sponsor
- University of LeedsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Manchester; Newcastle University; University of Oxford; The Leeds Teaching Hospitals NHS Trust; Beatson West of Scotland Cancer Centre; University of Glasgow; Velindre NHS Trust; University College London Hospitals; Queen's University, Belfast; University of Sheffield
- First posted
- Sep 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CONCORDE is a multi-institution, multi-arm, Phase IB study that will determine the recommended phase II dose (RP2D) and safety profiles of different DNA damage repair inhibitors (DDRis) when given in an open label fashion in combination with fixed dose curative intent radiotherapy (RT) in patients with stage IIB/IIIA/IIIB NSCLC, followed by up to 12 months of consolidation durvalumab immunotherapy in selected study arms. The RP2D will be evaluated by incorporating the number of observed dose limiting toxicities (DLTs) into a time to event continuous reassessment method (TiTE- CRM) model within each of the experimental arms. TiTE-CRM is used here to take into account longer-term toxicities up to 13.5 months post start of radiotherapy and use these to inform dose escalation decision making.
Conditions
- Non Small Cell Lung Cancer
Interventions
RadiotherapyRadiation
Administered as 30 fractions of 2Gy. Total 60 60Gy. Administered once daily monday to friday.
Olaparib Oral Tablet [Lynparza]Drug
Oral tablet
AZD1390Drug
Oral tablet
CeralasertibDrug
Oral Tablet
AZD5305Drug
Oral Tablet
DurvalumabDrug
1500mg iv infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose limiting ToxicitiesTime frame: 13.5 months after start of radiotherapy
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Belfast City Hospital
Belfast, United Kingdom · Recruiting
Birmingham Heartlands Hospital
Birmingham, United Kingdom · Recruiting
Addenbrooke's Hospital
Cambridge, United Kingdom · Recruiting
Velindre Cancer Centre
Cardiff, United Kingdom · Recruiting
The Royal Marsden Hospital Chelsea
Chelsea, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
St James's University Hospital
Leeds, United Kingdom · Recruiting
The Clatterbridge Cancer Centre
Liverpool, United Kingdom · Recruiting
St Bartholomew's Hospitals
London, United Kingdom · Recruiting
University College Hospital London
London, United Kingdom · Recruiting
The Christie NHS Foundation Trust
Manchester, United Kingdom · Recruiting
Freeman Hospital, Newcastle upon Tyne Hospitals NHS Trust
Newcastle upon Tyne, United Kingdom · Recruiting
Weston Park Hospital
Sheffield, United Kingdom · Recruiting
The Royal Marsden Sutton
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.